SEARCH
Enter your search term below:
Close
Enter your search term below:
WORLD LEADING BUSINESS SUPPORT
iQur is concentrating its therapeutic research and development on a vaccine platform based on exploiting the immune stimulant properties of Hepatitis B core. iQurÕs patented Tandem Core Technology (TCT) relies on the linkage of two HBV core molecules to form a stable backbone that combines to form virus like particles. Insertion of target antigens into the TCT produces a vaccine that combines the immune alert signal provided by the HBV core with targeting of the immune response to the inserted vaccine antigen. This technology can be used to generate immune responses against infectious pathogens including viruses, bacteria and parasites such and malaria, agents used in biodefence, anima pathogens and cancer associated antigens.
Get all the fresh insights first! Stay up-to-date with all the
latest investment news, blogs and all things SETsquared.
Close
A group of Bristol-based entrepreneurs has invested £192k into @SETsquared_Br member, #GenomeKey, a research and de… twitter.com/i/web/status/13519…
The prospect of launching & running a start-up can be daunting with many challenges to navigate.
That’s where SE… twitter.com/i/web/status/13518…
SETsquared Scale Up companies, @Data_Cubed_Ltd, @gen3d @SeabEnergy @Vitabeam_ have been selected to pitch to inves… twitter.com/i/web/status/13518…
5 reasons to take part in our next Digital Entrepreneur Workout:
No5: It’s attracting some rave reviews
Over 50… twitter.com/i/web/status/13515…
Congratulations to @SETsquaredExe members, #Freyda for successfully securing significant funding for their innovati… twitter.com/i/web/status/13514…
SETsquared is a partnership between